𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Thrombopoietic activity of recombinant human interleukin 11 in cancer patients receiving chemotherapy

✍ Scribed by Michael S. Gordon

Publisher
Springer
Year
1996
Tongue
English
Weight
71 KB
Volume
38
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Pharmacoeconomic analysis of oprelvekin
Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy
✍ Scott B. Cantor; Linda S. Elting; David V. Hudson Jr.; Edward B Rubenstein πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 315 KB

## Abstract ## BACKGROUND Previous research has shown oprelvekin (recombinant human interleukin‐11 [rhIL‐11]) to be effective in reducing the requirements for platelet transfusions after myelosuppressive chemotherapy in patients who have previously experienced thrombocytopenia. The economic conseq

Recombinant human interleukin-1 beta ana
Recombinant human interleukin-1 beta analogue as a regulator of hematopoiesis in patients receiving chemotherapy for urogenital cancers
✍ Tatsuo Iizumi; Satoshi Sato; Tetsuro Iiyama; Ryosuke Hata; Hiroshi Amemiya; Hiro πŸ“‚ Article πŸ“… 1991 πŸ› John Wiley and Sons 🌐 English βš– 331 KB

Ten patients with advanced urologic cancers who were scheduled to receive at least two courses of chemotherapy were enrolled in this trial. Fifty thousand units of recombinant human interleukin-1 (IL-1) beta analogue Ltd., Tokyo, Japan) was administered subcutaneously only once or twice when severe

In vivo activation of lymphocytes in mel
In vivo activation of lymphocytes in melanoma patients receiving escalating doses of recombinant interleukin 2
✍ Carlo Gambacorti-Passerini; Marina Radrizzani; Raffaele Marolda; Filiberto Belli πŸ“‚ Article πŸ“… 1988 πŸ› John Wiley and Sons 🌐 French βš– 705 KB

A phase-I study of the recombinant, non-mutagenized interleukin 2 (rlL2, Bioleukin'") was performed in 12 melanoma patients (Pts). From 100 to 800 pg/m2 of rlL2 were administered by i.v. bolus injection, TID for 4-8 days. Side-effects included fever, malaise, low serum K + and C a + + values, electr